Dr. Sapra is Vice-President, Tumor Targeted Delivery, in Oncology Research and Development at AstraZeneca, leading the group responsible for tumor-targeting technology platforms, including ADCs, nanoparticles, radioimmunoconjugates and oncolytic viruses, from target conception to clinic. She previously served as Vice-President and Chief Scientific Officer at Pfizer Inc. and led Pharmacology groups at Enzon Pharmaceuticals and Immunomedics Inc. Dr. Sapra has contributed to two approved agents, Mylotarg® and Besponsa®. Dr. Sapra has authored over 50 scientific publications and book chapters, and is an inventor/ co-inventor on over 25 patents. She serves as the Deputy Editor of Molecular Cancer Therapeutics. In 2017, Dr. Sapra was recognized as a Healthcare Business Women Association Rising Star.
Current role
Scientific Advisory Board Member at Confo Therapeutics
Scientific Advisory Board Member at Solarea Bio
Scientific Advisory Board Member at Solarea Bio
Scientific Advisory Board Member at Chan Zuckerberg Biohub
Scientific Advisory Board Member at Gaba Therapeutics